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2Abstract
Background: People diagnosed with cancer often self-administer complementary and 
alternative medicines (CAMs) to supplement their conventional treatments, improve health, or 
prevent recurrence. Flor-Essence® and Essiac® Herbal Tonics are commercially available 
complex mixtures of herbal extracts sold as dietary supplements and used by cancer patients 
based on anecdotal evidence that they can treat or prevent disease. In this study, we evaluated 
Flor-Essence® and Essiac® for their effects on the growth of human tumor cells in culture.
Methods: The effect of Flor-Essence® and Essiac® herbal tonics on cell proliferation was 
tested in MCF-7, MDA-MB-436, MDA-MB-231, and T47D cancer cells isolated from human 
breast tumors. Estrogen receptor (ER) dependent activation of a luciferase reporter construct was 
tested in MCF-7 cells. Specific binding to the ER was tested using an ICI 182,780 competition 
assay. 
Results: Flor-Essence® and Essiac® herbal tonics at 1%, 2%, 4% and 8% stimulated cell 
proliferation relative to untreated controls and activated ER dependent luciferase activity in MCF-
7 cells. A 10-7 M concentration of ICI 870,780 inhibited the induction of ER dependent luciferase 
activity by Flor-Essence® and Essiac®, but did not affect cell proliferation.
Conclusions: Flor-Essence® and Essiac® Herbal Tonics can stimulate the growth of 
human breast cancer cells through ER mediated as well as ER independent mechanisms of action. 
3Cancer patients and health care providers can use this information to make informed decisions 
about the use of these CAMs.
4Introduction
There is a pressing scientific need to understand the biologic effects of alternative 
therapies [1, 2]. Complementary and alternative medicine (CAM) is used by a reported 50% of 
the general public in North America [3-5] and among some patient populations CAM use is as 
high as 85% [4, 6, 7]. The use of CAM reflects the growing trend in the United States of turning 
to alternative medicines to replace or supplement conventional therapies [8]. The increased use of 
CAM is driven by many factors including increases in prices of prescription drugs, media reports 
of adverse effects of prescription drugs, managed health care- mandated restricted access to 
physician care, and importantly, free access to product information from the internet [9, 10]. 
Patients combine CAM and conventional approaches with a hope to improve quality of life, 
counter side effects, and achieve a sense of control over their therapy [11].
Essiac herbal extract formulations are commercially available from many sources and 
used as a CAM by some cancer patients and survivors. The two most widely used commercially 
available essiac herbal tonics are Flor-Essence® and Essiac®. Both formulations contain the same 
four basic herbs: burdock root (Arctium lappa), sheep sorrel (Rumex acetosella), slippery elm 
bark (Ulus rubra)and Turkish rhubarb (Rheum palmatum).  In addition, Flor-Essence® contains 
red clover (Trifolum pratense), blessed thistle (Carduus benedictus), kelp (Laminaria digitata), 
and watercress (Nasturt officinale). These herbal tonics are advertised to improve health and 
boost the immune system. Their use by cancer patients is largely fueled by anecdotal evidence 
that they can treat or prevent disease [7]. In a survey of 318 cancer patients treated by the Royal 
Mardsen Hospital in London, 6.0% reported using Essiac, one of the 5 most popular alternative 
remedies cited [11]. The particular popularity of Flor-Essence® and Essiac® as complementary 
therapies among breast cancer survivors and patients may be related to the first described use of 
5this herbal tonic as a cure for a breast lump [12-14]. In a recent field study, designed to determine 
which natural products were recommended by health food store employees to individuals seeking 
treatment for breast cancer, Flor-Essence® and Essiac ® were the two most frequently 
recommended products [15]. 
Flor-Essence® and Essiac® herbal tonics are marketed as dietary supplements and so not 
regulated by the FDA in the same way as are prescription and over the counter drugs [8, 9]. The 
available literature focusing on Flor-Essence® and Essiac® is widely disseminated in the lay 
press [13, 14, 16] and on numerous web sites and is rarely backed by scientific information [1, 2, 
14]. In spite of these approaches to capture the interest of consumers, patients are beginning to 
demand science-based information about herbal products with which to make informed decisions 
about their use [17]. Advising patients on the use of unconventional therapies is difficult when 
rigorous scientific data and documentation about their safety, efficacy, and potential herbal-drug 
interactions are unavailable [8, 9, 17].
Although the effects of the tonics have not been thoroughly studied, the effects of the 
individual herbs used in the Flor-Essence® and Essiac® have been investigated because of their 
important dietary and medicinal roles [18]. Characteristics of these herbs include estrogenic, 
cytotoxic, anti-estrogenic, anti-tumor, anti-mutagenic, anti-oxidant, and anti-inflammatory 
properties, among others. The lay literature suggests that the components act synergistically to 
convey beneficial properties [13, 14]; however, this has not been scientifically demonstrated [18].
We were interested in determining if Flor-Essence® and Essiac® tonics effect tumor cell 
growth either by estrogen-dependent or –independent mechanisms. Estrogenic activity was 
hypothesized since several of the herbal tonic components (burdock root, sheep sorrel, and red 
clover) contain phytoestrogens such as the isoflavones genistein, daidzein, formononetin, and 
6biochanin-A [18]. Genistein levels in red clover are ten-fold greater than in soy [18]. 
Administration of red clover to ovariectomized rats causes a dose-dependent increase in uterine 
wet weight, a biologic measure of estrogenic activity [19]. 
Several model systems can be used to evaluate complex mixtures for functional and 
biologic relevance to human exposure including in vitro cell proliferation and reporter assays, and 
in vivo uterotropic assays in rodents [20-29]. We report here our successful use of cell 
proliferation and estrogen receptor (ER)  dependent luciferase reporter assay systems to evaluate 
the effect of Flor-Essence® and Essiac® herbal tonics on cancer cell growth. Using these assays, 
we show that these tonics stimulate ER activation and dramatically increase breast cancer cell 
proliferation.
Materials and Methods:
Human Breast Cancer Cells
Estrogen receptor positive (ER+) MCF-7, and T47D, and estrogen receptor negative (ER-) 
MDA-MB-231 and MDA-MB-436 human breast cancer cell lines, obtained from American Type 
Culture Collection (ATCC, Manassas, VA), were used for the described studies. MCF-7 cells 
were grown in DMEM with 5% fetal bovine serum (FBS), 1% non-essential amino acids, 
10 µg/ml insulin, 2 mM L-glutamine, and 1% penicillin/streptomycin. MDA-MB-436 cells were 
grown in Leibovitz’z L-15 medium supplemented with 10 µg/ml insulin, 16 µg/ml glutathione, 
2mM L-glutamine, 1% penicillin/streptomycin, and 10% FBS. T47D cells were grown in RPMI 
1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L 
glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate and supplemented with 0.2 units/ml 
bovine insulin, 1% penicillin/streptomycin and 10% FBS. MDA-MB-231 cells were grown in 
7RPMI 1640 medium with 2 mM L-glutamine, 1% penicillin/streptomycin and 10% FBS. All cells 
were maintained at 37°C with 5% CO2
For cell proliferation assays and estrogen responsive reporter assays, Opti-MEM phenol red-
free medium (Gibco) was used with 5% charcoal stripped fetal bovine serum (Clonetech) to 
minimize estrogen-like activity contributed by the phenol red and serum [29, 30].
Herbal Tonic preparation 
Flor-Essence® (Flora Manufacturing) was obtained as a sterile pre-packaged and prepared 
product at a local health food store. It was used directly out of the bottle for the described tissue 
culture applications, which is how an individual who had purchased the product for self-
administration would consume it. Similarly, Essiac® (Reserpine Corporation) was obtained as a 
dry formulation, and was prepared in the laboratory as recommended by the manufacturer. Both 
tonics were kept refrigerated and not exposed to extremes in temperature in accordance with 
manufacturer’s instructions. 
Recommendations from the available lay literature on Essiac formulations suggest daily 
doses ranging from 1 to 6 oz [12, 13, 16]: However, dose recommendations are not based on 
weight and although the majority of people who self-administer Flor-Essence® herbal tonic self-
report following the recommended doses, some admit to consuming more [7]. Because the final 
concentration of tonic at the level of the target cells is unknown, making it difficult to mimic a 
human exposure, we chose a range of Flor-Essence® and Essiac® tonic concentrations (1% to 
32%) to evaluate a dose response. 
Cell proliferation assay
8For cell proliferation assays, 3 x 103 cells were seeded into each well of a 96-well tissue 
culture plate. Twenty-four hours after plating, cells were treated with Opti-MEM medium 
supplemented with 1%, 2%, 4%, or 8% Flor-Essence® or Essiac® herbal tonic, 10-7 to 10-10 M 
17-b-estradiol (E2) (Sigma), or left untreated. The effect of tonic exposure on cell growth was 
evaluated 24 and 72 hours after the initiation of treatment. For incubations longer than 24 hours, 
cell medium was renewed at the 48 hours time point. Flor-Essence® concentrations up to 32% 
were tested in the MCF-7 cell line. For the ICI 182,780 experiments, cells were pre-treated with 
10-7 M ICI 182,780  (Tocris Cookson, Inc., Ellisville MO) for 30 minutes, followed by 10-9 M E2, 
increasing concentrations of Flor-Essence® or Essiac®, or no treatment. 
Cell growth was quantified using an Aqueous Non-Radioactive Cell Proliferation Assay 
(Promega, Madison WI) with absorbance of the wells measured in a standard multi-well plate 
reader at 490nm. Briefly, this colormetric assay measures the bioreduction of a tetrazolium 
compound (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt; MTS) to a formazan product. The conversion of MTS is directly 
proportional to the number of living cells in culture. Each experiment was performed at least three 
individual times with 4 – 6 replicates per experiment. Effect of treatment was determined by 
comparing cell growth to the appropriate vehicle-treated cells (sterile water) and untreated cells 
and is presented as percent of control. Error is presented as standard error of the mean. Statistical 
significance was assessed using a standard Student’s T-test.
Estrogen Responsive Reporter Assay
Herbal tonic concentrations ranging from 1% to 8% were directly tested for estrogenic and 
anti-estrogenic activity using a standard estrogen responsive reporter plasmid containing three 
9vitellogenin estrogen responsive elements (EREs) upstream of the luciferase reporter gene 
(EREx3-Luc). EREx3-Luc was co-transfected with a commercially available control renilla 
reporter plasmid (pRL-TK, Promega) to control for transfection efficiency and for the 
normalization of the results. The reporter plasmids were transfected into MCF-7 cells [31-34], 
which have well-characterized responses to estrogenic stimuli. The ability of the herbal tonics to 
induce luciferase reporter gene activity was compared to 10-9 M E2 and appropriate negative 
controls, as previously described [35, 36].
MCF-7 cells were plated in 96-well plates, designed specifically for use in a luminometer 
(Perkin Elmer, Wellesley, MA) at a density of 1X105 cells/well in Opti-MEM medium. The cells 
were left untransfected or were co-transfected with 200 ng each of luciferase reporter and renilla 
control plasmids using lipofectAMINE™ 2000 (Invitrogen) optimized for 96-well plate 
experiments according to directions. After a 5-hour transfection, the untransfected cells were 
incubated with culture medium made from Opti-MEM and 5% charcoal stripped FBS to quantify 
background levels. The transfected cells were incubated with the same culture media alone or 
supplemented with 1%, 2%, 4%, or 8% Essiac® or Flor-EssenceÒ herbal tonics.
The cells were incubated at 37°C for 18 hours and then assayed for luciferase and renilla 
activity using a dual luciferase/renilla reporter assay kit (Promega) according to directions. Each 
experimental condition was duplicated six to eight times in the 96-welled plate and each plate was 
read in the luminometer twice. Luciferase activity was normalized to the renilla controls. 
Co-incubating the cells with 10-9 M E2 and increasing concentrations of both tonics was 
used to measure potential anti-estrogenic activity. To indirectly measure specific binding to the 
ER, the anti-estrogen ICI 182,780 was added to the cells and the change in Flor-Essence® and 
Essiac®-mediated induction of luciferase activity was measured. Transfected cells were exposed 
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to 10-7 M ICI 182,780 for 30 minutes before addition of 10-9 M E2, 4% Flor-Essence®, or 4% 
Essiac®.
All experiments were repeated more than 4 times (with 5-6 replicates per experiment) and 
all data were normalized to E2 (10-9M) activation. Error is presented as standard error of the 
mean. Statistical significance was determined using a standard Student’s T-test.
Results
Flor-Essence® and Essiac® Herbal Tonic induce human breast cancer cell proliferation at low 
concentrations.
Flor-EssenceÒ treatment was associated with a statistically significant increase in cell 
proliferation that ranged from 1.5-fold to 2.1-fold (p < 0.01) (Figure 1A) at 24 hours after 
treatment. The increase in cell growth was similar for all cell lines tested, regardless of ER status. 
In addition, these concentrations resulted in a greater induction of cell growth than estrogen alone 
(10-10 M or 10-9 M), which was 1.1-fold greater than control in the MCF-7 cell line (data not 
shown). Concentrations of Flor-Essence® up to 32% were tested in the MCF-7 cell line; 
treatment with 16% Flor-EssenceÒ resulted in growth that was not significantly different from 
controls and 32% was cytotoxic to the cells (data not shown). These concentrations were not used 
in subsequent experiments.
The 1%, 2%, 4%, and 8% Essiac® treatments induced proliferation 1.2-fold to 2.2-fold 
above untreated cells (Figure 1B) 24 hours after exposure and was statistically significant 
(p < 0.01, with the exception of MCF-7 cells treated with 8% Essiac®, which was p < 0.05). The 
ER+ MCF-7 cells were less stimulated by Essiac® treatment relative to other cell lines tested 
(p<0.01). However the T47D ER+ cell line, showed proliferation that was not significantly 
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different than the ER- cell lines. All Essiac® concentrations tested induced proliferation to a 
greater degree than 10-10 M or 10-9 M E2 in any cell line at 24 hours after treatment (data not 
shown). 
Comparing the response of the 4 cell lines to the two tonics demonstrated that Flor-
Essence® and Essiac® produced a generally similar increase in cell proliferation in the T47D, 
MDA-MB-436 and the MDA-MB-231 cell lines.  In the MCF-7 cells, Flor-Essence® produced a 
statistically significant increased proliferation at all concentrations tested (p<0.01), compared to 
Essiac®. In addition, low concentrations of Flor-Essence® (1% ) produced a significant increase 
in proliferation in the ER- cell lines, when compared to Essiac®.
To determine if continuous exposure would result in an acute increase in cell proliferation 
followed by acclimation and a return to basal levels or a sustained increase in cell proliferation we 
treated the cell lines for extended periods of time with the two tonics at multiple concentrations. 
Cells were treated with 4% Flor-Essence® (Figure 2A) or 4% Essiac® (Figure 2B) for up to 72 
hours. Induced proliferation was significantly different than control (p <0.01, with the exception 
of 72 hours treatment of the T47D cells, which was p < 0.05) although the effect of increasing 
time of tonic treatment was not the same for all cell lines tested.  For T47D, MDA-MB-436, and 
Essiac®-treated MDA-MB-231, the increased cell proliferation demonstrated in the 24 hour time 
point was not sustained at 72 hours tonic treatment. Flor-Essence®- treated MDA-MB-231 cells 
and Essiac®-treated MCF-7 cells showed a time-dependent increase in cell proliferation (72 hrs > 
24 hrs, p<0.01) and Flor-Essence®-treated MCF-7 cells showed no difference in the 24 and 72 
hour time points.
The time-dependent effects of two tonics were not significantly different for the T47D or 
MDA-MB-436 cells lines. However, 24 hour incubation with Flor-Essence® caused a significant 
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increase in MCF-7 cell proliferation compared to Essiac® (also demonstrated in Figure 1). 
Similarly, 72 hours incubation with Flor-Essence® produced a statistically significant increase in 
cell proliferation in the MDA-MB-231 cells, compared to Essiac® (p<0.01).
Flor-Essence® and Essiac® induce estrogen-receptor dependent luciferase reporter activity
Both the Essiac® and Flor-Essence® herbal tonics induced luciferase expression from an 
ER dependent reporter construct transfected into MCF-7 cells. Flor-Essence® administered at 
1%, 2%, 4%, and 8% induced luciferase activity 3.8-, 4.9-, 5.0-, and 3.3-fold over negative 
controls and was statistically significant (p < 0.0001; Figure 3). Lower concentrations of Flor-
Essence® (1%, 2%, and 4%) produced luciferase induction that was not statistically different 
from the 4.5-fold increase observed with 10-9 M E2 relative to the negative control. MCF-7 cells 
exposed to 1%, 2%, 4% and 8% Essiac® induced luciferase activity 2.8-, 3.1-, 3.4-, and 3.9-fold 
above untreated controls (p < 0.0001). However, the induced luciferase activity was significantly 
less than cells treated with 10-9 M E2 (p < 0.01) or low concentrations of Flor-Essence®. One, 2 
and 4% Flor-Essence® caused significantly more luciferase induction compared to the same 
concentrations of Essiac®. The effect of 8% Flor-Essence® treatment was significantly less than 
the effect of 10-9 M E2 and not significantly different from the same concentration of Essiac®
(p < 0.01).
Genistein, a known phytoestrogen, was also tested in the luciferase assay and induced 
estrogen receptor dependent luciferace expression. Genistein concentrations of 0.1 ug/ml and 1 
ug/ml elicited a 5.1- and 5.0-fold greater luciferase expression than the negative control that was 
statistically significant (p < 0.01) (Figure 3). This response is similar to that observed for 2% and 
4% Flor-Essence® and not significantly different from E2 exposure. A low genistein 
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concentration (0.01 ug/ml) did not induce luciferase activity above control. Similarly, a relatively 
high genistein concentration of 10 ug/ml was not efficient at inducing luciferase activity.
To test for potential anti-estrogenic activity, 1%, 2%, 4% and 8% Flor-Essence® and 1%, 
2%, 4% and 8% Essiac® were co-incubated with 10-9 M E2 in the luciferase assay.  Combining 
the tonic exposure with E2 did not significantly affect E2 induction of luciferase expression (data 
not shown).
Effect of ICI 182,780 on Flor-Essence® and Essiac® induced luciferase activity and cell 
proliferation
ICI 182,780 is an anti-estrogen that specifically antagonizes the binding of the estrogen-
receptor binding to its natural ligand at the estradiol binding site [37, 38]. If a compound is acting 
through an estrogen-receptor dependent mechanism of action, ICI 182,780 will inhibit mediation 
of the effect. ICI 182,780 pre-treatment followed by 10-10 M E2 caused a 7.2-fold reduction in 
luciferase activity compared to 10-10 M E2 alone. Pre-treatment with ICI 182,780 before exposure 
to 4% Flor-Essence® and 4% Essiac® caused a 4.6- and 3.3-fold decrease in luciferase activity, 
respectively (Figure 4A). 
To determine if specific binding of ICI 182,780 to the ER produced a parallel inhibition of 
cell proliferation, cells were treated with ICI 182,780 for 30 minutes prior to treatment with 2% 
and 4% Flor-Essence® or Essiac®.  Cell proliferation was measured after 24 hours incubation. 
Figure 4B shows that incubation with ICI produced no significant reduction in cell proliferation, 
compared to tonic treatment alone. However, pre-treatment with ICI 182,780 prevented E2-
mediated increases in cell proliferation. Longer incubation times (48 hours) or repeating the
experiment in the MDA-MB-436 cell line did not change the results (data not shown). 
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Discussion
In this paper we demonstrate for the first time that both Essiac® and Flor-Essence® herbal 
tonics stimulate cell growth in ER+ and ER- breast cancer cell lines and can activate ER 
dependent transcription. The results of the transcriptional activation studies provide mechanistic 
information to suggest that specific components within the tonic activate the ER. Based on our 
knowledge of the ingredients in these two tonics, it is likely that phytoestrogens such as genestein, 
daidzein, formononetin, and biochanin-A are responsible for this activity. However, because the 
tonics are equally able to stimulate growth in ER- cell lines and in the presence of the anti-
estrogen ICI 182,780, our results also suggest that the tonics are able to affect growth through 
other, ER independent pathways. In fact, the various components of these complex mixtures may 
be acting together with the phytoestrogens to increase cell proliferation through ER dependent 
mechanisms, ER independent mechanisms, or receptor cross-talk with subsequent estrogen 
responsive element (ERE) binding.
The effect of the tonics on cell proliferation was tested using a modified E-SCREEN assay 
[39].  This assay was developed to take advantage of the ability of estrogen-responsive MCF-7 
cells to proliferate in the presence of compounds that mimic estrogen.  Although a standard assay 
for estrogenicity screening, the proliferative response of the MCF-7 cells varies depending on the 
MCF-7 sub-line employed.  In these studies we used ATCC wild-type MCF-7 cells, which have 
been shown to vary in their response to estrogen incubation [39]. Using this assay, we 
demonstrated that Essiac® and Flor-Essence® herbal tonics stimulate cell proliferation to a 
greater degree than estradiol treatment in the MCF-7 cells. 
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Further modification of the E-SCREEN assay to accommodate different media conditions 
enabled us to test additional ER+ and ER- human breast cancer cell lines. Using this approach, we 
demonstrated that Flor-Essence® and Essiac® herbal tonics induced the proliferation of T47D, 
MDA-MB-231 and MDA-MB-436 breast cell lines at concentrations ranging from 1 to 8%, 
regardless of the presence of the ER. Mechanistically, this suggests that the ER is not necessary 
for the proliferative effect of Essiac® and Flor-Essence®. Evaluating cell proliferation after the 
co-administration of the anti-estrogen ICI 182, 780 and the tonics further supports the conclusion 
that the ER is not essential for the cell growth effect.  In these experiments we demonstrate that 
specifically blocking the estradiol binding site on the ER did not significantly affect the ability of 
the tonics to stimulate cell proliferation.  
We investigated the effect of chronic exposure to the tonic by incubating the cell lines 
with Flor-Essence® and Essiac® for up to 72 hours.  Prolonged exposure to the two tonics 
resulted in an increase in cell proliferation that continued with exposure. The cells did not 
acclimate to the exposure by returning to the baseline or control growth rate during the 3 day 
exposure time course. This may indicate that a long duration of exposure to the tonics (as would 
be expected, based on the recommended dosing regime in the product literature) could result in 
continued stimulation of cell proliferation of human breast cells. 
Both tonics are able to activate ER-dependent transcription in MCF-7 cells transfected 
with a standard estrogen responsive luciferase reporter plasmid, indicating that the tonics can 
interact with the endogenous ER present in MCF-7 cells to effect transcription. Tonic-induced ER 
activation suggests that although these tonics are complex mixtures of herbal extracts, estrogenic 
activity contributed by constituent components are detectable and can be correlated with effects 
on cell growth. Sheep sorrel and burdock root are present in Flor-Essence® and Essiac® and red 
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clover is a component of Flor-Essence® all there extracts are reported to contain phytoestrogens, 
which may be directly interacting with the ER.
ICI 182,780 is an anti-estrogen that specifically binds the ER and blocks estrogen binding. 
This compound was used to investigate the interaction of components of Flor-Essence® and 
Essiac® at the level of the ER in the transcription assay. Pre-incubation with ICI 182,780 
inhibited tonic-stimulated increased luciferase activity, suggesting that the tonics effect 
transcription through direct interaction with ER at the estradiol binding site. ER activity was 
reduced, but not completely abolished, by the addition of ICI 182,780 suggesting that the tonics 
may activate ER transcription via mechanisms that do not rely on direct binding to the estradiol 
binding site. In addition, pre-incubation with ICI 182, 780 in cell proliferation studies had no 
effect on the ability of the tonics to increase cell growth, further suggesting that the tonics can 
stimulate cell proliferation by mechanisms that do not involve direct interaction with the estradiol 
site on the ER. 
Although there was little difference in the effects of the two tonics on cell proliferation, 
Flor-Essence® tended to produce a greater response in the ER+ MCF-7 cell line.  This 
observation, in combination with the luciferase assay, suggests that the additional components 
present in Flor-Essence®, relative to Essiac®, including red clover, blessed thistle, kelp, and 
watercress, may be enhancing the response. Red clover has high genistine levels and the inclusion 
of this plant extract may explain the increased estrogenic activity of Flor-Essence® herbal tonic 
compared to Essiac®. 
Genistein was included in these studies in order to compare the tonics to a known 
phytoestrogen, which has been well investigated in both in vitro and in vivo models for breast 
cancer as well as in epidemiologic studies [40-46].  In the study presented here, 2% and 4% Flor-
17
Essence® induce luciferase activity at levels similar to 0.1 ug/ml and 1.0 ug/ml genistein. As 
expected, 10ug/ml genestein demonstrated a reduced ability to stimulate estrogen receptor 
activation, possibly by down regulating ER- alpha expression [47].  This trend is similar to the 
results we obtained with increasing concentrations of tonic exposure. 
Two other studies have been recently published, demonstrating the effect of Essiac®
and/or Flor-Essence® on human cell lines [48, 49].  Ottenweller et.al. demonstrated decreased 
cell proliferation of  Chinese Hamster Ovary (CHO) cells and the human prostate cancer cell line, 
LNCaP.  This study also demonstrated an augmentation of T-cell proliferation at low doses of 
Essiac® [48].  The study by Tai, et. al. reported a slight increase in cell proliferation in ATCC 
MCF-7 cells at 1 and 2 % tonic concentrations. The results of the Tai study also show a weak 
antiproliferative effect of both Flor-Essence® and Essiac® on 3 cancer cell lines at doses 
spanning 1-10% tonic at 96 h incubation time and a differentiation inducing effect on HL60 cells 
at high concentrations [49]. 
It is difficult to directly compare our results to those presented by Otenweller et al and Tai 
et al. because of the difference in cell lines used as well as the different approaches to study 
design. We took precautions to ensure that our assay systems were depleted of estrogenic 
components. We chose to use Opti-MEM phenol red free medium, which is often used when 
testing compounds in cell systems to determine if they are estrogenic [29, 30]). In addition, 
although we used normal fetal bovine serum in our medium for the routine propagation of our cell 
lines, we used charcoal stripped fetal bovine serum for the cell proliferation and estrogen 
responsive reporter assays. These conditions are designed to minimize the contributions of 
estrogenic activity from the cell medium in order to fully detect those present in the herbal tonics. 
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Bi-phasic bioactivity (causing activation at low concentrations and inhibition at high 
concentrations) has been reported for at least two naturally-occurring estrogenic compounds [50, 
51].  By not depleting the culture conditions of inherent estrogens, and then adding the tonics, it is 
possible that the total concentration of estrogenic compounds in the assay system was never low 
enough in the Tai et al study to determine an activation effect.  We also found that high 
concentrations of Flor-Essence® (16-32%) did not cause a stimulatory effect or inhibited cell 
proliferation. 
Another factor complicating cross-study comparisons across is product consistency. 
Herbal tonics are sold as dietary supplements, are not regulated, are not standardized and may 
demonstrate lot-to-lot variability. The Tai et al study used HPLC to evaluate the lots used for 
their study and found no significant differences among lots. We have also evaluated lot variation 
of Flor-Essence® and Essiac® using HPLC and proliferation assays (data not shown).  Our HPLC 
results found some variation in the peak height of the various components of the herbal tonics in 
different lots, but the proliferation assays consistently showed a cell growth stimulatory effect.
In this report, we have demonstrated that Flor-Essence® and Essiac® can promote the 
growth of cancer cells and that ER- dependent and independent mechanisms are responsible for 
mediating the effect. In a previous study, we showed that Flor-Essence® promoted DMBA-
initiated mammary tumor formation in Sprague-Dawley rats [52].  The present study provides the 
rational for a mechanistic basis for the increase in tumor multiplicity seen in the rat study. 
DMBA-induced rat mammary tumors are hormone sensitive and it is likely that ER mediated 
growth effects are playing a role in tumor growth. However, due to the complex nature of the 
herbal mixtures there are likely to be an array of components that affect cell growth through 
alternative mechanisms.
19
Cancer patients are desperately seeking information about CAM and frequently seek that 
information from the internet. Highly credible cancer websites exist that provide reliable 
information about CAM for cancer treatment and prevention with links to information on CAM. 
However others websites issue misleading information including, but not limited to, claims for 
CAM efficacy that are not supported by sound scientific evidence or advice for patients that 
counsels against conventional therapy [53]. Essiac is frequently mentioned as a “curative” CAM 
[53] and over 90% of the websites that mentioned FlorEssence® were considered questionable 
due to vague, inaccurate, anecdotal and nonscientific information [54]. It has been estimated that 
50% of internet users use the World Wide Web to gather medical information and that this 
information can influence a patient’s choice of treatments [53, 55, 56].  Thus, there is a strong 
need for both accurate information and peer-reviewed studies in order that informed decisions can 
be made when one is considering self-administering CAM. Individuals and health care providers 
can use the information presented in this report to begin evaluating the risks and benefits of self-
administration of Essiac® and Flor-Essence® herbal tonics in the context of individual health 
needs and concerns. For women and men who have been diagnosed with cancer, these results may 
be significant and can be used to make informed decisions about herbal tonic use.
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Figure Legends:
Figure 1:  Effect of herbal tonic dose on ER+ and ER- human breast cancer cell 
proliferation.  Cells were treated for 24 hours with increasing concentrations of A: Flor-Essence®
and B: Essiac®. All tonic concentrations stimulated proliferation significantly above control (p < 
0.01), with the exception of a, which is p< 0.05. b= Flor-Essence® significantly greater than the 
same concentration of Essiac®, p<0.01. c= Flor-Essence® significantly greater than the same 
concentration of Essiac®, p<0.05.
Figure 2: Effect of herbal tonic time of incubation on ER+ and ER- human breast cancer 
cell proliferation.  Cells were treated with 4% Flor-Essence® (A) or 4% Essiac® (B) for up to 72 
hours. All times are significantly greater than control, p<0.01, with the exception of (a) which is 
greater than control, p<0.05. b= Flor-Essence® significantly greater than Essiac®, p<0.01.
Figure 3.  Effect of herbal tonics and genistein on ER activation.  MCF-7 cells were left 
untreated (Ctrl) or treated with 10 –10M estradiol (E2), or increasing concentrations of Flor-
Essence®,         Essiac®,          or genistein.           Genistein concentrations are µg/ml. Data are 
normalized to estrogen. a= significantly different from control, p<0.01. b= significantly different 
from estradiol, p<0.01. c= significantly different than the same concentration of Flor-Essence®, 
p<0.01.
Figure 4.  Effect of ICI 182,780 on Flor-Essence®- and Essiac®- induced luciferase gene 
expression and cell proliferation in MCF-7 cells. A. Cells were treated with estradiol (10-10M), 
Control 1% 2% 4% 8%
0 h hhrss 24 h h 72h
30
4% Flor-Essence® (F-E®) and 4% Essiac® (Es®) with and without ICI 182,780 (ICI) (10-7M).  
Data are normalized to estrogen. a = significantly different from treatment without ICI 182,780, 
p<0.01. B. Cells were treated with 2 and 4% Flor-Essence® (F-E®) and 2 and 4% Essiac® (Es®) 
with and without ICI 182,780 (ICI)(10-7M) for 24 hours.  Data are normalized to control. All 
treatments (except for E2) were significantly different than control, p<0.01. E2 w/ ICI was 
significantly different than either control or E2 alone, p<0.01. There is no statistical difference 
between the cells treated with just tonic and cells treated with tonic and ICI. Other incubation 
times were tested with no change in results. 
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